Can-Fite shareholders approve three proposals

Can-Fite BioPharma Ltd. reported that a Special General Meeting of Shareholders held on March 10, 2026 approved all three proposals presented to shareholders.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. reported that a Special General Meeting of Shareholders held on March 10, 2026 approved all three proposals presented to shareholders. These proposals were previously outlined in the company’s Notice and Proxy Statement dated January 27, 2026, which had been furnished on Form 6-K.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Can-Fite BioPharma (CANF) disclose in its March 2026 Form 6-K?

Can-Fite BioPharma disclosed that shareholders at a Special General Meeting on March 10, 2026 approved all three proposals presented. Those proposals were previously described in the company’s January 27, 2026 Notice and Proxy Statement furnished as an exhibit to an earlier Form 6-K.

When was Can-Fite BioPharma’s Special General Meeting of Shareholders held?

The Special General Meeting of Shareholders was held on March 10, 2026. At this meeting, Can-Fite BioPharma’s shareholders voted on three proposals and approved each one in accordance with the required majority, as later reported in the company’s March 2026 Form 6-K filing.

How many proposals did Can-Fite BioPharma shareholders approve at the March 2026 meeting?

Shareholders approved three proposals at the March 10, 2026 Special General Meeting. The Form 6-K notes that each proposal received the required majority, and that all three had been previously described in the January 27, 2026 Notice and Proxy Statement sent to shareholders.

Where can investors find details about the proposals approved by Can-Fite BioPharma shareholders?

Details on the approved proposals are in Can-Fite BioPharma’s Notice and Proxy Statement dated January 27, 2026. That document was attached as Exhibit 99.1 to a Form 6-K furnished to the U.S. Securities and Exchange Commission on the same January 27, 2026 date.

What type of SEC filing did Can-Fite BioPharma use to report the shareholder vote?

Can-Fite BioPharma used a Form 6-K, which is a report of a foreign private issuer. The filing states that the company’s March 10, 2026 Special General Meeting of Shareholders approved all three proposals described in an earlier proxy statement furnished on January 27, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/10/2026 - 04:30 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of March 2026

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On March 10, 2026, a Special General Meeting of Shareholders of Can-Fite BioPharma Ltd. (the “Company”) approved each of the three proposals brought before the Company’s shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company’s Notice and Proxy Statement with respect to the Company’s Special General Meeting of Shareholders, dated January 27, 2026, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on January 27, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 10, 2026	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

Source: View Original Filing on SEC EDGAR